Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2025 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2025 Earnings Call Transcript May 12, 2025Arcturus Therapeutics Holdings Inc. beats earnings expectations.
Arcturus Therapeutics Holdings Inc. (ARCT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 2,008,480 | $21,269,803 | +4% | 0.21% |
| 2. | Balyasny Asset Management Dmitry Balyasny | 938,190 | $9,935,432 | +71% | 0.02% |
| 3. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 825,766 | $8,744,860 | -3% | 0.05% |
| 4. | Woodline Partners Michael Rockefeller And Karl Kroeker | 780,442 | $8,264,881 | -4% | 0.05% |
| 5. | Millennium Management Israel Englander | 461,907 | $4,891,595 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.00 | 2,222 | $39,996.00 | 24,942 | 2022-12-15 | Filing | |
| $16.51 | 5,000 | $82,550.00 | 1,480,097 | 2022-11-23 | Filing | |
| $33.33 | 450 | $14,998.50 | 950 | 2020-06-12 | Filing | |
| $31.69 | 1,000 | $31,690.00 | 1,475,097 | 2020-06-10 | Filing | |
| $29.74 | 5,000 | $148,700.00 | 273,245 | 2020-06-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.76 | 12,000 | $249,121.20 | 435,334 | 2024-10-15 | Filing | |
| $32.03 | 50,000 | $1,601,500.00 | 220,526 | 2024-06-12 | Filing | |
| $45.00 | 114 | $5,130.00 | 447,334 | 2024-06-05 | Filing | |
| $40.01 | 26,000 | $1,040,234.00 | 447,448 | 2024-06-03 | Filing | |
| $35.02 | 17,435 | $610,573.70 | 473,448 | 2024-03-25 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,694,060 | $49,710,095 | 0.11% | |
| 2. | 2,759,970 | $29,228,082 | 0% | |
| 3. | 1,926,084 | $20,397,230 | 0.01% | |
| 4. | 1,926,084 | $20,377,969 | 0.26% | |
| 5. | 1,748,928 | $18,521,147 | 0% |
News See All
10 Worst High-Risk High-Reward Growth Stocks To Buy
On March 14, Tom Lee managing partner and head of research at Fundstrat Global Advisors appeared on a CNBC interview to talk about how the markets react to crises and what approach investors should take...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2024 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2024 Earnings Call Transcript March 6, 2025Arcturus Therapeutics Holdings Inc. misses on earnings expectations.
10 Worst ARK Stocks To Buy According to Short Sellers
Cathie Wood of ARK Investment is one of Wall Street's most well-known hedge fund bosses.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2024 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2024 Earnings Call Transcript November 7, 2024Arcturus Therapeutics Holdings Inc. beats earnings expectations.
10 Worst ARK Stocks To Buy According To Short Sellers
Investing comes in all sizes and flavors. For the risk averse investors that are looking for steady payouts or long term stability, value and dividend paying stocks are the way to go.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2024 Earnings Call Transcript
Operator: Greetings and welcome to Arcturus Therapeutics' Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Arcturus Therapeutics First Quarter 2024 Earnings Call. At this time, all lines are in listen-only mode.
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we discuss 12 most undervalued biotech stocks to buy according to hedge funds.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. beats earnings expectations. Reported EPS is $-0.32, expectations were $-1.69.
Billionaire Hedge Funds
